Cytek Biosciences (NASDAQ:CTKB - Get Free Report) will likely be announcing its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect Cytek Biosciences to post earnings of ($0.04) per share and revenue of $43.18 million for the quarter.
Cytek Biosciences Stock Performance
Shares of CTKB stock traded down $0.03 on Tuesday, hitting $3.78. The stock had a trading volume of 179,772 shares, compared to its average volume of 710,492. The firm has a market capitalization of $481.69 million, a price-to-earnings ratio of -47.18 and a beta of 1.42. The stock's 50 day moving average is $3.97 and its 200-day moving average is $5.30. Cytek Biosciences has a 52-week low of $3.27 and a 52-week high of $7.63.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. The Goldman Sachs Group set a $5.25 target price on shares of Cytek Biosciences in a report on Sunday, February 2nd. Stephens reissued an "overweight" rating and issued a $6.00 target price on shares of Cytek Biosciences in a report on Wednesday, March 19th. Finally, Piper Sandler decreased their target price on Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th.
Get Our Latest Stock Analysis on Cytek Biosciences
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Featured Articles
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
